UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 12, 2004
SOLUTIA INC.
------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE
--------
(STATE OF INCORPORATION)
001-13255 43-1781797
--------- ----------
(COMMISSION (IRS EMPLOYER
FILE NUMBER) IDENTIFICATION NO.)
575 MARYVILLE CENTRE DRIVE, P.O. BOX 66760, ST. LOUIS, MISSOURI 63166-6760
- --------------------------------------------------------------- ----------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
(314) 674-1000
--------------
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE
ITEM 9. REGULATION FD DISCLOSURE.
The following information is being furnished under Item 9.
"Regulation FD Disclosure." Solutia Europe SA/NV, a subsidiary of Solutia
Inc., has retained the investment banking firm of Rothschild Inc. to explore
strategic options for its Pharmaceutical Services business, which accounts
for approximately 2 percent of the annual revenue of Solutia Inc. These
options include a potential sale of the Pharmaceutical Services business,
which includes the businesses now conducted by two Swiss subsidiaries of
Solutia Europe SA/NV. For any sale to occur, Solutia Europe SA/NV would need
to obtain the consent of its Euro Note bondholders as further provided in
the definitive documentation for the Euro Notes. There is no assurance that
any such sale will occur.
The information in Item 9 shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to
the liabilities of that section.
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE
REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE
UNDERSIGNED, THEREUNTO DULY AUTHORIZED.
SOLUTIA INC.
----------------------------------
(Registrant)
/s/ Rosemary L. Klein
---------------------
Secretary
DATE: July 12, 2004